Literature DB >> 20964739

Circulating cardiovascular biomarkers in recurrent atrial fibrillation: data from the GISSI-atrial fibrillation trial.

R Latini1, S Masson, S Pirelli, S Barlera, G Pulitano, E Carbonieri, M Gulizia, T Vago, C Favero, D Zdunek, J Struck, L Staszewsky, A P Maggioni, M G Franzosi, M Disertori.   

Abstract

OBJECTIVE: we evaluated the prognostic role of circulating cardiovascular biomarkers in patients with a history of recent atrial fibrillation (AF).
BACKGROUND: predicting long-term maintenance of sinus rhythm in patients with AF is difficult.
METHODS: plasma concentrations of three specific cardiac markers [high-sensitivity troponin T (hsTnT), N-terminal probrain natriuretic peptide (NT-proBNP) and mid-regional proatrial natriuretic peptide (MR-proANP)] and three stable fragments of vasoactive peptides [mid-regional proadrenomedullin (MR-proADM), copeptin (CT-proAVP) and CT-proendothelin-1 (CT-proET-1)] were measured at baseline and after 6 and 12 months in 382 patients enrolled in the GISSI-AF study, a prospective randomized trial to determine the effect of valsartan to reduce the recurrence of AF. The association between these markers, clinical characteristics and recurrence of AF was tested by univariate and multivariate Cox models.
RESULTS: mean patient age was 68 ± 9 years (37.2% females). A total of 84.8% of patients had a history of hypertension. In total, 59.7% qualified for history of AF because of successful cardioversion, 11.8% because of two or more episodes of AF in the 6 months preceding randomization and 28.5% because of both. Patients in AF at 6 or 12 months (203 (53.1%) with first recurrence) had significantly higher concentrations of most biomarkers. Despite low baseline levels, higher concentrations of hsTnT {adjusted hazard ratio (HR) [95% confidence intervals (CIs) for 1 SD increment] (1.15 [1.04-1.28], P = 0.007), MR-proANP (1.15 [1.01-1.30], P = 0.04), NT-proBNP (1.24 [1.11-1.39], P = 0.0001) and CT-proET-1 (1.16 [1.01-1.33], P = 0.03) independently predicted higher risk of a first recurrence of AF. Changes over time of MR-proANP tended to predict subsequent recurrence (adjusted HR [95%CI]) (1.53 [0.98-2.37], P = 0.06).
CONCLUSION: circulating markers of cardiomyocyte injury/strain and endothelin are related to recurrence of AF in patients in sinus rhythm with a history of recent AF.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20964739     DOI: 10.1111/j.1365-2796.2010.02287.x

Source DB:  PubMed          Journal:  J Intern Med        ISSN: 0954-6820            Impact factor:   8.989


  23 in total

1.  Relation between soluble ST2, growth differentiation factor-15, and high-sensitivity troponin I and incident atrial fibrillation.

Authors:  Michiel Rienstra; Xiaoyan Yin; Martin G Larson; João D Fontes; Jared W Magnani; David D McManus; Elizabeth L McCabe; Erin E Coglianese; Michael Amponsah; Jennifer E Ho; James L Januzzi; Kai C Wollert; Michael G Fradley; Ramachandran S Vasan; Patrick T Ellinor; Thomas J Wang; Emelia J Benjamin
Journal:  Am Heart J       Date:  2013-10-17       Impact factor: 4.749

Review 2.  Recent advances in the molecular pathophysiology of atrial fibrillation.

Authors:  Reza Wakili; Niels Voigt; Stefan Kääb; Dobromir Dobrev; Stanley Nattel
Journal:  J Clin Invest       Date:  2011-08-01       Impact factor: 14.808

Review 3.  Atrial fibrillation: current knowledge and future directions in epidemiology and genomics.

Authors:  Jared W Magnani; Michiel Rienstra; Honghuang Lin; Moritz F Sinner; Steven A Lubitz; David D McManus; Josée Dupuis; Patrick T Ellinor; Emelia J Benjamin
Journal:  Circulation       Date:  2011-11-01       Impact factor: 29.690

Review 4.  Comprehensive risk reduction in patients with atrial fibrillation: emerging diagnostic and therapeutic options--a report from the 3rd Atrial Fibrillation Competence NETwork/European Heart Rhythm Association consensus conference.

Authors:  Paulus Kirchhof; Gregory Y H Lip; Isabelle C Van Gelder; Jeroen Bax; Elaine Hylek; Stefan Kaab; Ulrich Schotten; Karl Wegscheider; Giuseppe Boriani; Axel Brandes; Michael Ezekowitz; Hans Diener; Laurent Haegeli; Hein Heidbuchel; Deirdre Lane; Luis Mont; Stephan Willems; Paul Dorian; Maria Aunes-Jansson; Carina Blomstrom-Lundqvist; Maria Borentain; Stefanie Breitenstein; Martina Brueckmann; Nilo Cater; Andreas Clemens; Dobromir Dobrev; Sergio Dubner; Nils G Edvardsson; Leif Friberg; Andreas Goette; Michele Gulizia; Robert Hatala; Jenny Horwood; Lukas Szumowski; Lukas Kappenberger; Josef Kautzner; Angelika Leute; Trudie Lobban; Ralf Meyer; Jay Millerhagen; John Morgan; Felix Muenzel; Michael Nabauer; Christoph Baertels; Michael Oeff; Dieter Paar; Juergen Polifka; Ursula Ravens; Ludger Rosin; W Stegink; Gerhard Steinbeck; Panos Vardas; Alphons Vincent; Maureen Walter; Günter Breithardt; A John Camm
Journal:  Europace       Date:  2011-07-26       Impact factor: 5.214

5.  Biomarkers in electrophysiology: role in arrhythmias and resynchronization therapy.

Authors:  Abhishek Bose; Quynh A Truong; Jagmeet P Singh
Journal:  J Interv Card Electrophysiol       Date:  2015-02-27       Impact factor: 1.900

6.  High-sensitivity cardiac troponin T and the risk of incident atrial fibrillation: the Atherosclerosis Risk in Communities (ARIC) study.

Authors:  Kristian B Filion; Sunil K Agarwal; Christie M Ballantyne; Maria Eberg; Ron C Hoogeveen; Rachel R Huxley; Laura R Loehr; Vijay Nambi; Elsayed Z Soliman; Alvaro Alonso
Journal:  Am Heart J       Date:  2014-10-22       Impact factor: 4.749

Review 7.  Evaluating the Atrial Myopathy Underlying Atrial Fibrillation: Identifying the Arrhythmogenic and Thrombogenic Substrate.

Authors:  Jeffrey J Goldberger; Rishi Arora; David Green; Philip Greenland; Daniel C Lee; Donald M Lloyd-Jones; Michael Markl; Jason Ng; Sanjiv J Shah
Journal:  Circulation       Date:  2015-07-28       Impact factor: 29.690

8.  B-type natriuretic peptide and C-reactive protein in the prediction of atrial fibrillation risk: the CHARGE-AF Consortium of community-based cohort studies.

Authors:  Moritz F Sinner; Katherine A Stepas; Carlee B Moser; Bouwe P Krijthe; Thor Aspelund; Nona Sotoodehnia; João D Fontes; A Cecile J W Janssens; Richard A Kronmal; Jared W Magnani; Jacqueline C Witteman; Alanna M Chamberlain; Steven A Lubitz; Renate B Schnabel; Ramachandran S Vasan; Thomas J Wang; Sunil K Agarwal; David D McManus; Oscar H Franco; Xiaoyan Yin; Martin G Larson; Gregory L Burke; Lenore J Launer; Albert Hofman; Daniel Levy; John S Gottdiener; Stefan Kääb; David Couper; Tamara B Harris; Brad C Astor; Christie M Ballantyne; Ron C Hoogeveen; Andrew E Arai; Elsayed Z Soliman; Patrick T Ellinor; Bruno H C Stricker; Vilmundur Gudnason; Susan R Heckbert; Michael J Pencina; Emelia J Benjamin; Alvaro Alonso
Journal:  Europace       Date:  2014-07-18       Impact factor: 5.214

Review 9.  [Biomarkers and atrial fibrillation : Prediction of recurrences and thromboembolic events after rhythm control management].

Authors:  Jelena Kornej; Katja Schumacher; Daniela Husser; Gerhard Hindricks
Journal:  Herzschrittmacherther Elektrophysiol       Date:  2018-05-14

10.  Natriuretic Peptides as Predictors of Atrial Fibrillation Recurrences Following Electrical Cardioversion.

Authors:  Theodoros A Zografos; Demosthenes G Katritsis
Journal:  Arrhythm Electrophysiol Rev       Date:  2013-11-29
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.